Pathstone Family Office’s Neurocrine Biosciences NBIX Stock Holding History

Pathstone Family Office’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$323K	Buy	+2,870	New	+$302K	﹤0.01%	1266
2023 Q1	–	Sell	-2,091	Closed	-$250K	–	1401
2022 Q4	$250K	Buy	2,091 +33	+2%	+$3.87K	﹤0.01%	1303
2022 Q3	$219K	Buy	+2,058	New	+$209K	﹤0.01%	1310
2017 Q4	–	Sell	-250	Closed	-$15K	–	189
2017 Q3	$15K	Buy	+250	New	+$13.2K	0.01%	114

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pathstone Family Office's NBIX Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Neurocrine Biosciences (NBIX) in Q3 2023: 2,870 shares worth $323K. The stake represents ﹤0.01% of the portfolio and ranks #1266 among its holdings. This is a return to the name: Pathstone Family Office previously reported a position in NBIX as recently as Q4 2022.

Pathstone Family Office first reported a position in NBIX in Q3 2017 and has held it in 4 quarters since. 511 funds tracked by Wall St. Rank hold NBIX as of Q3 2023.

Pathstone Family Office held 2,870 shares of Neurocrine Biosciences worth $323K as of Q3 2023.
Neurocrine Biosciences was a new Pathstone Family Office position in Q3 2023.
Neurocrine Biosciences made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1266 holding.
Pathstone Family Office first reported a position in Neurocrine Biosciences in Q3 2017 and has held it in 4 quarters since.
511 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.